Cisplatin (DDP) is the first-line chemotherapeutic drug for
non-small cell lung cancer (NSCLC), and long-term DDP stimulation increased resistance of NSCLC cells to this drug by enriching cancer stem cells (CSCs), which contributed to recurrence and worse prognosis of NSCLC, but the molecular mechanisms are still not fully delineated.
METHODS: Real-Time qPCR and Western Blot analysis were conducted to examine gene expressions at
mRNA and
protein levels, respectively. Dual-
luciferase reporter gene system was used to validate the targeting sites among
circRNA CDR1as, miR-641 and HOXA9
mRNA. Cell growth was evaluated by
CCK-8 assay,
trypan blue staining assay and colony formation assay. The
Annexin V-FITC/PI double staining method was employed to measure cell apoptosis ratio. Spheroid formation and flow cytometer assay was used to evaluate cell stemness. Xenograft mice models were established to measure tumorgenicity in vivo, and Ki67 expressions in mice
tumor tissues were examined by immunohistochemistry (IHC).
RESULTS: Here we identified a novel
circRNA CDR1as/miR-641/
Homeobox protein Hox-A9 (HOXA9) pathway regulated stemness and DDP chemoresistance in NSCLC. Mechanistically,
circRNA CDR1as and HOXA9 were high-expressed, while miR-641 was low-expressed in DDP-resistant NSCLC cells, instead of their corresponding parental DDP-sensitive NSCLC cells. Additionally, we validated that
circRNA CDR1as positively regulated HOXA9 in NSCLC cells by serving as an
RNA sponge for miR-641, and knock-down of
circRNA CDR1as increased the sensitivity of DDP-resistant NSCLC cells, which were reversed by downregulating miR-641 and upregulating HOXA9. Consistently, overexpression of
circRNA CDR1as increased drug resistance of DDP-sensitive NSCLC cells by regulating miR-641/HOXA9 axis. In addition, the expression levels of stemness signatures (SOX2, OCT4 and Nanog) were higher in DDP-resistant NSCLC cells, which also tended to form spheres and enrich CD44+CD166+ population compared to their parental DDP-sensitive NSCLC cells, suggesting that CSCs were enriched in DDP-resistant NSCLC cells. Notably, knock-down of
circRNA CDR1as inhibited stemness of DDP-resistant NSCLC cells by inhibiting HOXA9 through upregulating miR-641.
CONCLUSIONS: Taken together, this study identified that
circRNA CDR1as regulated stemness and DDP chemoresistance in NSCLC cells by targeting miR-641/HOXA9 axis.